<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533906</url>
  </required_header>
  <id_info>
    <org_study_id>LOA_19_04</org_study_id>
    <nct_id>NCT04533906</nct_id>
  </id_info>
  <brief_title>Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses</brief_title>
  <official_title>Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinomed Biotech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinomed Biotech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of&#xD;
      the study is to determine whether the iota-carrageenan content in the saliva of subjects who&#xD;
      sucked Coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common&#xD;
      respiratory viruses causing common cold. At least 29 subjects will be screened, in order to&#xD;
      get 24 subjects included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coldamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of&#xD;
      the study is to determine whether the iota-carrageenan content in the saliva of subjects who&#xD;
      sucked Coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common&#xD;
      respiratory viruses causing common cold. At least 29 subjects will be screened, in order to&#xD;
      get 24 subjects included.&#xD;
&#xD;
      The primary objective is whether the mean iota-carrageenan concentration in saliva during&#xD;
      sucking an iota-carrageenan containing lozenge reaches published IC90 values for HRV1a and&#xD;
      HRV8.&#xD;
&#xD;
      The secondary objectives are whether the mean iota-carrageenan concentration in saliva&#xD;
      (µg/ml; base line corrected) during sucking an iota-carrageenan containing lozenge reaches&#xD;
      the respective IC90/MIC values (paired t-tests) of the clinical saliva samples for HRV1a,&#xD;
      HRV8, hCoV OC43, influenza virus H1N1n and Coxsackie virus A10.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Actual">November 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The saliva of subjects will be collected before and during sucking a Coldamaris lozenge.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the iota-carrageenan concentration in saliva.</measure>
    <time_frame>3 months</time_frame>
    <description>The mean iota-carrageenan concentration in saliva during sucking an iota-carrageenan containing lozenge should reach published IC90 values for 2 human rhinoviruses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome measure is the iota-carrageenan concetration in salvia.</measure>
    <time_frame>3 months</time_frame>
    <description>Iota-carrageenan concentration in saliva of subjects should be high enough to inhibit replication of human rhinoviruses, human Coronavirus OC43, human influenzavirus H1N1n, and Coxsackievirus A10.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Common Cold</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>Carrageenan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects sucking carageenan containing lozenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coldamaris lozenges</intervention_name>
    <description>sucking carageenan containing lozenge</description>
    <arm_group_label>Carrageenan</arm_group_label>
    <other_name>Betadine</other_name>
    <other_name>Quixx protect</other_name>
    <other_name>Quixx grip-protect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  personally signed and dated informed consent&#xD;
&#xD;
          -  healthy respiratory tract, no acute infection&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects with signs of an acute respiratory infection&#xD;
&#xD;
          -  subjects with a known hypersensitivity to one of the ingredients&#xD;
&#xD;
          -  presence of pregnancy confirmed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Friedrich Ehrenreich</name>
      <address>
        <city>Vienna</city>
        <zip>1170</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>respiratory virus</keyword>
  <keyword>carrageenan</keyword>
  <keyword>coronavirus</keyword>
  <keyword>influenza virus</keyword>
  <keyword>human rhinovirus</keyword>
  <keyword>coxsackie virus</keyword>
  <keyword>Carragelose</keyword>
  <keyword>Iota-carrageenan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

